What Is a Continuous Glucose Monitor?

A Continuous Glucose Monitor (CGM) is a medical-grade wearable device that measures glucose levels in real time, typically updating every one to five minutes. Unlike conventional blood glucose meters that require a finger-stick blood sample and provide only a single point-in-time reading, CGMs deliver a continuous data stream that reveals glucose trends, rate-of-change arrows, and patterns over hours and days. This continuous view empowers users to take proactive action before glucose enters a dangerous range, making CGMs a cornerstone of modern diabetes management for both type 1 and type 2 diabetes, and increasingly for people with prediabetes or general metabolic health optimization.

The system consists of three core components: a sensor that is inserted just beneath the skin, a transmitter that relays data wirelessly, and a display device such as a smartphone app, smartwatch, or dedicated receiver. The sensor stays in place for 7 to 14 days (or up to six months for implantable versions) and is typically replaced by the user at home. The transmitter sends glucose readings via Bluetooth Low Energy or radiofrequency to the display, where the user can view a real-time glucose number, a trend graph, and receive customizable alerts for high or low glucose thresholds.

How CGMs Work: The Core Technology

Understanding how a CGM works requires looking at both the biological principle and the electromechanical design that makes continuous monitoring possible. While the user experience is seamless, the technology behind the sensor is surprisingly intricate.

The Sensor: A Tiny Electrochemical Lab

The sensor is a thin, flexible filament (typically 5–6 mm long and less than 0.5 mm wide) that is inserted into the subcutaneous tissue using a spring-loaded applicator. It rests in the interstitial fluid—the fluid that bathes cells—not in a blood vessel. This is a critical distinction: interstitial fluid glucose (ISF) lags behind blood glucose, which we will discuss in detail later.

On the sensor’s tip, a tiny working electrode is coated with the enzyme glucose oxidase. This enzyme is immobilized in a layer that also includes a mediator (in some designs) or relies on the natural production of hydrogen peroxide. The sensor also contains a counter electrode and a reference electrode to complete the electrochemical cell.

How the reaction works:

  • Glucose from the interstitial fluid diffuses into the sensor and reacts with glucose oxidase, producing gluconic acid and hydrogen peroxide (H2O2).
  • The hydrogen peroxide is then oxidized at the working electrode under a constant applied voltage (~0.6 V), releasing two electrons per molecule.
  • This electron flow creates a tiny electrical current (amperometric signal) measured in nanoamperes. The current is directly proportional to the glucose concentration in the interstitial fluid.

The sensor’s outer membrane plays a vital role: it limits the rate of glucose diffusion to the enzyme layer, extends the sensor’s linear range, and excludes interfering molecules such as acetaminophen, ascorbic acid, and uric acid. Manufacturers like Dexcom and Abbott use proprietary membrane formulations that dramatically reduce interference compared to earlier CGM models. For instance, the latest-generation sensors use a permselective membrane that selectively allows glucose to pass while blocking larger or charged molecules.

The Transmitter: Processing and Broadcasting the Signal

The transmitter attaches directly to the sensor housing and contains the electronics needed to measure the tiny current, convert it to a glucose value, and send that data wirelessly. Inside the transmitter there is an amperometric circuit that applies a precise voltage and measures the current. The raw current is then processed by a digital signal processor that applies calibration factors, filtering algorithms, and checks for quality indicators (such as signal stability or motion artifacts).

Most modern CGMs use a one-step factory calibration process where the sensor’s sensitivity is stored in the transmitter during manufacturing. This eliminates the need for regular finger-stick calibration, though some older or implantable systems still require periodic blood glucose meter comparisons to maintain accuracy.

Data is transmitted to the display device using Bluetooth Low Energy (BLE), which minimizes power consumption and allows the transmitter to run for 7–14 days on a small coin cell or rechargeable battery. The transmission frequency varies—some systems send data every 5 minutes, while others stream every minute or on-demand when a user opens the app.

The Display Device and Software

The display is typically a smartphone app that receives the incoming glucose data and presents it in a user-friendly interface. The app shows the current glucose value, a trend arrow indicating the direction and speed of change (e.g., “rising quickly” or “falling slowly”), and a graph of the last 3–24 hours. Users can scroll back through historical data, add meal or exercise markers, and view summary statistics such as Time-in-Range (TIR), average glucose, and standard deviation.

Alerts are a critical safety feature. The user can set thresholds for high and low glucose, and many systems also offer predictive alerts that sound before the glucose actually crosses the threshold, based on the rate of change. For example, the Dexcom G7 can alert you 20 minutes before a predicted low, giving you time to eat a snack. Some apps also allow real-time data sharing with caregivers or clinicians, improving safety for children or elderly users.

Interstitial Fluid Versus Blood: Understanding the Lag

One of the most frequently misunderstood aspects of CGM technology is the physiological lag between blood glucose and interstitial fluid glucose. Glucose moves from capillaries into the interstitial space via diffusion. During periods of stable glucose, blood and ISF values are nearly identical. But during rapid changes—such as after a carbohydrate-rich meal, during intense exercise, or after a fast-acting insulin bolus—ISF glucose can trail behind blood glucose by 5 to 15 minutes.

CGM manufacturers use predictive algorithms to compensate for this lag. For example, the algorithm may estimate what the blood glucose is likely to be in 10–15 minutes based on recent trends. This works well in most situations, but during rapid falls, the displayed glucose may still be slightly higher than the true blood value, leading to a delayed hypoglycemia alert. For severe hypoglycemia, it is still prudent to confirm with a finger-stick before treating, especially if symptoms do not match the reading.

It’s also worth noting that sensor location matters. Sensors placed on the abdomen, upper arm, or thigh all have slightly different perfusion rates and may exhibit different lag characteristics. Abbott’s FreeStyle Libre recommends the back of the upper arm, while Dexcom allows several insertion sites. Users should observe their own patterns and be aware that alternative sites may show a slightly larger lag.

Types of CGM Systems on the Market

The CGM market is dominated by three major players, with a fourth offering an implantable alternative. Each system has a unique balance of wear time, accuracy, calibration needs, and integration capabilities.

Dexcom G7

The Dexcom G7 is an all-in-one sensor/transmitter unit that lasts 10 days. It requires no finger-stick calibration (factory-calibrated), provides real-time readings with predictive alerts, and connects directly to a smartphone app and smartwatch. It also integrates with automated insulin delivery systems like Tandem t:slim X2 and Omnipod 5. Its accuracy is among the best in the market, with a MARD (mean absolute relative difference) of approximately 8–9%. The G7 is slightly smaller than its predecessor (G6) and starts transmitting within 30 minutes of insertion.

Abbott FreeStyle Libre 3

The Libre 3 offers the longest wear time among disposable sensors at 14 days. It is factory-calibrated and requires zero finger sticks for routine use. It is also the smallest sensor on the market—roughly the size of two stacked pennies. The Libre 3 uses automatic data transmission to a smartphone app (no scanning required, unlike earlier Libre versions). Abbott’s sensor uses a unique glucose-oxidase formulation with improved interference rejection. Its MARD is around 7–8%, making it highly competitive. The Libre platform does not yet offer predictive alerts for lows, but it does have customizable high and low alarms.

Medtronic Guardian 4

Medtronic’s Guardian 4 sensor works exclusively with Medtronic insulin pumps (MiniMed 780G and earlier). It has a 7-day wear period and requires twice-daily calibration via finger-stick. Its strength lies in its integration with Medtronic’s SmartGuard algorithm, which suspends insulin delivery when low glucose is predicted, or automatically adjusts basal rates. The MARD is about 9–10%. It is more cumbersome than newer competitors but remains an essential choice for Medtronic pump users.

Senseonics Eversense E3

The Eversense E3 is the only fully implantable CGM on the market. A small sensor is inserted under the skin (usually in the upper arm) by a healthcare provider in a minor office procedure. It lasts up to 6 months. A removable transmitter worn on the skin above the sensor powers the system and communicates with the smartphone app. The transmitter must be removed and recharged daily. The Eversense has demonstrated excellent accuracy with a MARD of about 8–9% and has a unique feature: on-body vibrotactile alerts that can wake the user during the night without sounding an audible alarm. The downsides include the need for a surgical insertion and removal, and it requires twice-daily calibration during the first 21 days, then daily calibration thereafter. For some users, the lack of a frequent sensor change and the discreet alerts are major advantages.

Clinical Benefits: What the Evidence Shows

Large-scale clinical trials have firmly established the benefits of CGM for people with diabetes. Key findings include:

  • Reduced HbA1c: In the landmark DIAMOND trial, adults with type 1 diabetes using CGM experienced a 0.6% reduction in HbA1c compared to usual care (finger-stick alone). Similar results were seen in type 2 diabetes.
  • Decreased Hypoglycemia: CGM use significantly reduces the time spent in hypoglycemia (<70 mg/dL), especially in individuals with hypoglycemia unawareness. The ability to receive alerts before a low occurs prevents many dangerous episodes.
  • Improved Time-in-Range: An increase of 1–3 hours per day within the target range (70–180 mg/dL) is consistently observed. Each 5% improvement in TIR correlates with reduced risk of retinopathy and nephropathy.
  • Quality of Life: Users report less anxiety about glucose levels, better sleep (fewer finger-stick interruptions), and greater confidence in making treatment decisions.

Limitations and Current Challenges

Despite their transformative impact, CGMs are not perfect. Key limitations include:

  • Accuracy at extremes: MARD tends to rise during hypoglycemia and hyperglycemia. The FDA requires CGM systems to achieve a MARD below 20%, but topical variations can occur.
  • Cost and insurance access: CGM sensors can cost $200–400 per month without insurance. While coverage is expanding, it is still not universal for type 2 diabetes not using insulin or for prediabetes.
  • Skin irritation: The adhesive required to keep the sensor attached for days or weeks can cause contact dermatitis or allergic reactions. Some users need barrier products or alternative adhesives.
  • Sensor lifespan: Most sensors last only a week or two, requiring frequent manual replacement. This can be inconvenient and forgetfulness can lead to gaps in data.
  • Interference: Certain medications, especially high-dose acetaminophen (>2000 mg/day) and hydroxyurea, can artificially elevate CGM readings. Users should read manufacturer warnings and check package inserts.

Choosing a CGM: Key Considerations for Users

With multiple options on the market, selecting the right CGM depends on personal factors. Here are the main decision points:

  • Wear time: Do you prefer to change a sensor every 7 days, 10 days, 14 days, or every 6 months? Longer wear reduces inconvenience but may require a more invasive insertion process.
  • Calibration: Factory-calibrated sensors (Dexcom G7, Libre 3) eliminate finger-sticks completely, while others (Guardian 4, Eversense) require periodic finger-stick calibration. For needle-averse or elderly users, zero calibration is a major advantage.
  • Integration: If you use an insulin pump, choose a CGM that integrates with it (Dexcom with Tandem or Omnipod; Medtronic with their own pumps). Smartwatch integration and data sharing are also important for many.
  • Alerts and notifications: Predictive low-glucose alerts are available on Dexcom and Medtronic, but not on Abbott Liberty (only threshold alarms). For those with hypoglycemia unawareness, predictive alerts are essential.
  • Cost: Out-of-pocket costs vary widely. Check insurance coverage and compare manufacturer discount programs. Abbott often has the lowest per-sensor cost for the Libre 3, while implantable sensors may have higher upfront costs but fewer replacement supplies.

The Future of Continuous Glucose Monitoring

Innovation in CGM technology is accelerating rapidly. Here are the most promising developments that will shape the next decade:

Longer-Lasting Sensors

Research into biocompatible coatings and improved enzyme stability aims to extend disposable sensor life to 30–45 days. Implantable sensors like Eversense already achieve 6 months, and next-generation versions may reach a year. This would dramatically reduce waste and user burden.

Non-Invasive CGMs

Many companies are racing to develop truly non-invasive glucose monitors that do not require any skin penetration. Techniques being explored include near-infrared spectroscopy, Raman spectroscopy, photoacoustic imaging, and transdermal reverse iontophoresis. While several devices have been commercialized (e.g., GlucoWatch in the early 2000s), none have yet achieved the accuracy needed for clinical decision-making when glucose is rapidly changing. Recent advances in machine learning to correct motion artifacts may finally bring a non-invasive CGM to market in the next 5 years.

Integration with Automated Insulin Delivery (AID) Systems

Already, CGM data is the backbone of hybrid closed-loop systems that automatically adjust insulin delivery. The next step is fully automated bi-hormonal systems that also deliver glucagon to prevent hypoglycemia. Projects like the OpenAPS community pioneered this DIY approach, and commercial versions are now in clinical trials. As algorithms become more sophisticated, the goal is a true “artificial pancreas” that requires little to no user input.

Artificial Intelligence and Predictive Analytics

Machine learning models trained on thousands of CGM traces can now predict glucose levels 30–60 minutes ahead with high accuracy. Companies like Dexcom and Abbott are integrating such models into their apps to provide proactive recommendations (e.g., “Consider a carbohydrate correction now to avoid a low in 25 minutes”). These predictive features will become more common and may soon drive insulin dosing decisions without user intervention.

Expanded Access and Lower Cost

As manufacturing scales and competition intensifies, sensor prices are expected to fall. Already, generic and biosimilar CGM sensors are being developed. Non-profit organizations and governments are also working to make CGM accessible in low- and middle-income countries, where diabetes burden is high but finger-stick testing remains the norm.

Conclusion

Continuous Glucose Monitors have revolutionized diabetes management by replacing pain, guesswork, and isolated data points with a continuous, actionable view of glucose dynamics. The underlying technology—a miniature electrochemical sensor, advanced algorithms, and wireless connectivity—harnesses decades of biosensor research to deliver life-changing benefits: fewer high and low excursions, reduced HbA1c, improved quality of life, and deeper understanding of glucose patterns. While challenges like cost, accuracy at extremes, and sensor lifespan remain, the pace of innovation is unstoppable. As CGMs become more accurate, more affordable, and more seamlessly integrated with automated insulin delivery and AI, they will continue to reduce the burden of diabetes and improve outcomes for millions worldwide. For the latest clinical recommendations, consult the American Diabetes Association and International Society for Pediatric and Adolescent Diabetes.